These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1672 related articles for article (PubMed ID: 26471290)

  • 41. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
    Mok TS; Wu YL; Thongprasert S; Yang CH; Chu DT; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; Yang JJ; Chewaskulyong B; Jiang H; Duffield EL; Watkins CL; Armour AA; Fukuoka M
    N Engl J Med; 2009 Sep; 361(10):947-57. PubMed ID: 19692680
    [TBL] [Abstract][Full Text] [Related]  

  • 44. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
    Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
    Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
    Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
    Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
    Macedo-Pérez EO; Morales-Oyarvide V; Mendoza-García VO; Dorantes-Gallareta Y; Flores-Estrada D; Arrieta O
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):681-90. PubMed ID: 25059320
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.
    Rotella V; Fornaro L; Vasile E; Tibaldi C; Boldrini L; Chella A; D'Incecco A; Cirigliano G; Chioni A; Lupi C; Sensi E; Ginocchi L; Giovannelli S; Pennucci MC; Fontanini G; Baldini E
    J Exp Clin Cancer Res; 2014 Oct; 33(1):77. PubMed ID: 25300933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
    Price KA; Azzoli CG; Krug LM; Pietanza MC; Rizvi NA; Pao W; Kris MG; Riely GJ; Heelan RT; Arcila ME; Miller VA
    J Thorac Oncol; 2010 Oct; 5(10):1623-9. PubMed ID: 20871262
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Kang EJ; Min KH; Hur GY; Lee SY; Shim JJ; Kang KH; Oh SC; Seo JH; Kim JS
    Chemotherapy; 2016; 61(1):41-50. PubMed ID: 26517706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
    Dhillon S
    Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
    Takeda M; Yamanaka T; Seto T; Hayashi H; Azuma K; Okada M; Sugawara S; Daga H; Hirashima T; Yonesaka K; Urata Y; Murakami H; Saito H; Kubo A; Sawa T; Miyahara E; Nogami N; Nakagawa K; Nakanishi Y; Okamoto I
    Cancer; 2016 Apr; 122(7):1050-9. PubMed ID: 26828788
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
    Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
    Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic Impact of DNA Repair Protein Expression in Non-Small Cell Lung Cancers Treated with Platinum-Based Chemotherapy and Subsequent Curative Lung Resection.
    Shin J; Lee KS; Yoh KA; Cho HJ; Choi MK; Kim SH; Kim YJ; Chung JH; Cho S; Kim K; Jheon S; Yoon HI; Lee JH; Lee CT; Lee JS
    Oncology; 2018; 95(1):20-30. PubMed ID: 29694959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
    Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.
    Fu P; Pennell NA; Sharma N; Yi Q; Dowlati A
    Rev Recent Clin Trials; 2017; 12(1):51-58. PubMed ID: 27633965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 84.